Vancomycin dry powder inhalation - Savara Pharmaceuticals

Drug Profile

Vancomycin dry powder inhalation - Savara Pharmaceuticals

Alternative Names: AeroVanc; Vancomycin hydrochloride inhalation powder

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Savara Pharmaceuticals
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity No
  • Available For Licensing Yes - Methicillin-resistant Staphylococcus aureus infections

Highest Development Phases

  • Phase III Methicillin-resistant Staphylococcus aureus infections
  • Phase I Bronchiectasis
  • Preclinical Nosocomial pneumonia

Most Recent Events

  • 30 Sep 2017 Phase-III clinical trials in Methicillin-resistant Staphylococcus aureus infections (In children, In adolescents, In adults, In the elderly) in USA (Inhalation) (NCT03181932)
  • 08 May 2017 Savara Pharmaceuticals has patent protection for vancomycin dry powder inhalation in USA
  • 08 May 2017 Savara Pharmaceuticals receives patent allowance for vancomycin dry powder inhalation in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top